Please assess the completion status of the following clinical trial:

Trial Title: Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male/female subjects from 16 years (where legally permitted and ethically accepted) or 18 years onwards suffering from epilepsy and having completed a previous study with brivaracetam as adjunctive treatment, which allowed access to this study~* Subjects with POS/PGS: inpatients or outpatients with epilepsy who participated in previous brivaracetam studies / programs which allow access to the present study~* Subjects with ULD: inpatients or outpatients with epilepsy who were treated with brivaracetam in previous studies / programs which allow access to the present study~* Subjects for whom the Investigator believes a reasonable benefit from the long-term administration of brivaracetam may be expected~Exclusion Criteria:~* Severe medical, neurological and psychiatric disorders, or laboratory values which may have an impact on the safety of the subject~* Poor compliance with visit schedule or medication intake in previous brivaracetam study~* Participation in any clinical study of another investigational drug or device during the study~* Pregnant or lactating woman

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brivaracetam (Type: EXPERIMENTAL): Flexible dosing, can up and down titrate as needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).